Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Kaliki, Swathi; Ayyar, Anuradha; Nair, Akshay G; Mishra, Dilip K; Reddy, Vijay Anand P; Naik, Milind N
• Is Part Of: Ophthalmic plastic and reconstructive surgery. Volume 32:Issue 1(2016:Jan./Feb.)
• Publication Date: 2016-01
• Subjects: Eye -- Surgery -- Periodicals; Ophthalmic plastic surgery -- Periodicals; Reconstructive Surgical Procedures -- Periodicals; Ophthalmologic Surgical Procedures -- Periodicals; Ophthalmology -- Periodicals; Surgery -- Periodicals; 617.70592
• DOI: 10.1097/IOP.0000000000000398
• Languages: English
• ISSNs: 0740-9303

Abstract

Abstract : Purpose: To report the efficacy of neoadjuvant systemic chemotherapy in the management of eyelid sebaceous gland carcinoma (SGC). Methods: Retrospective study of 10 patients that received neoadjuvant systemic chemotherapy (Cisplatin/Carboplatin and 5-Fluorouracil) for eyelid SGC. Results: The mean age at presentation of eyelid SGC was 58 years (median, 55 years; range, 45 to 72 years). There were 6 females and 4 males. The mean tumor basal diameter was 36 mm (median, 31 mm, range, 20 to 65 mm), with orbital tumor extension in 9 cases. On the basis of TNM Classification, the tumors were classified as T3 (n = 10), N1 (n = 6), and M1 (n = 2). The mean number of cycles of neoadjuvant systemic chemotherapy per patient was 3 (median, 3; range, 3 to 4). The mean percentage reduction of tumor basal diameter after neoadjuvant chemotherapy was 74% (median, 80%; range, 30% to 100%). None of them had any major systemic side-effects of neoadjuvant chemotherapy. Postchemotherapy, surgical treatment for residual tumor was performed in 7 cases. Five cases underwent excision biopsy and 2 cases with residual orbital component underwent eyelid-sparing orbital exenteration. No tumor recurrence was noted in any of the 7 cases at a mean follow-up period of 18 months (median, 14 months; range, 3 to 63 months). One patient died due to systemic metastasis. Conclusion: Neoadjuvant systemic chemotherapy is effective and safe in the management of eyelid sebaceous gland carcinoma. Abstract : Neoadjuvant systemic chemotherapy for eyelid sebaceous gland carcinoma, achieved a mean tumor size reduction of 74% (median, 80%; range, 30% to 100%) in our series of 10 cases.